High-throughput drug repositioning for the discovery of new treatments for chagas disease

Mini-Reviews in Medicinal Chemistry

Volumn 15, Issue 3, 2015, Pages 182-193

  Bellera, Carolina L ^a   Sbaraglini, Maria L ^a   Balcazar, Darío E ^b   Fraccaroli, Laura ^b   Cristina Vanrell, M ^b   Florencia Casassa, A ^b   Labriola, Carlos A ^c   Romano, Patricia S ^b   Carrillo, Carolina ^b   Talevi, Alan ^a  

^a UNIVERSIDAD NACIONAL DE LA PLATA   (Argentina)

^b Facultad de Ciencias Naturales e Instituto M Lillo   (Argentina)

^c FUNDACIÓN INSTITUTO LELOIR   (Argentina)

Author keywords

Chagas disease; Computer guided drug repositioning; Drug repositioning; Drug repurposing; High throughput drug repurposing; Indication expansion; Neglected diseases

Indexed keywords

AMIODARONE; BENIDIPINE; BENZNIDAZOLE; BROMOCRIPTINE; CEFOPERAZONE; CELECOXIB; CLOFAZIMINE; COLCHICINE; CRUZIPAIN; ENALAPRIL; ESCITALOPRAM; FEXINIDAZOLE; LEVOTHYROXINE; POSACONAZOLE; RAVUCONAZOLE; RIFABUTIN; RISEDRONIC ACID; SAQUINAVIR; SILDENAFIL; VERAPAMIL; ANTITRYPANOSOMAL AGENT; BENZOFURAN; BENZOFURAN DERIVATIVE;

ANTIPROLIFERATIVE ACTIVITY; ANTIPROTOZOAL ACTIVITY; ARTICLE; BIOINFORMATICS; CHAGAS DISEASE; COMPUTER AIDED DESIGN; DRUG BINDING SITE; DRUG EFFICACY; DRUG REPOSITIONING; DRUG SAFETY; DRUG TARGETING; ENZYME INHIBITION; GENE EXPRESSION PROFILING; GROWTH INHIBITION; HIGH THROUGHPUT SCREENING; HUMAN; NEGLECTED DISEASE; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); QUANTITATIVE STRUCTURE ACTIVITY RELATION; SEQUENCE HOMOLOGY; TRYPANOSOMA CRUZI; VOLUME OF DISTRIBUTION; BIOLOGY; CHEMISTRY; DRUG EFFECTS;

BENZOFURANS; CHAGAS DISEASE; COMPUTATIONAL BIOLOGY; DRUG REPOSITIONING; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; TRYPANOCIDAL AGENTS; TRYPANOSOMA CRUZI;

EID: 84930986248     PISSN: 13895575     EISSN: 18755607     Source Type: Journal    
DOI: 10.2174/138955751503150312120208     Document Type: Article

References (87)

1. World Health Organization. Chagas disease(American trypanosomiasis). Fact sheet N°340. http://www. who. int/mediacentre/factsheets/fs340/en/(accessed September 9, 2014).
2. Chatelain, E.; Ioset, J. R., Drug discovery and development for neglected diseases: the DNDi model. Drug Des. Devel. Ther., 2011, 5, 175-181.
3. Chirac, P.; Torreele, E., Global framework on essential health R&D. Lancet, 2006, 367(9522), 1560-1561.
4. Trouiller, P.; Torreele, E.; Olliaro, P.; White, N.; Foster, S.; Wirth, D.; Pecoul, B., Drugs for neglected diseases: a failure of the market and a public health failure? Trop. Med. Int. Health, 2001, 6(11), 945-951.
5. Moran, M.; Guzman, J.; Ropars, A. L.; McDonald, A.; Jameson, N.; Omune, B.; Ryan, S.; Wu, L., Neglected disease research and development: how much are we really spending? PLoS Med., 2009, 6(2), e30.
6. Lee, B. Y.; Bacon, K. M.; Bottazzi, M. E.; Hotez, P. J., Global economic burden of Chagas disease: a computational simulation model. Lancet Infect. Dis., 2013, 13(4), 342-348.
7. Nunes, M. C.; Dones, W.; Morillo, C. A.; Encina, J. J.; Ribeiro, A. L., Chagas disease: an overview of clinical and epidemiological aspects. J. Am. Coll. Cardiol., 2013, 62(9), 767-776.
8. Coura, J. R.; Dias, J. C., Epidemiology, control and surveillance of Chagas disease: 100 years after its discovery. Mem. Inst. Oswaldo. Cruz., 2009, 104 Suppl 1, 31-40.
9. McKerrow, J. H.; Doyle, P. S.; Engel, J. C.; Podust, L. M.; Robertson, S. A.; Ferreira, R.; Saxton, T.; Arkin, M.; Kerr, I. D.; Brinen, L. S.; Craik, C. S., Two approaches to discovering and developing new drugs for Chagas disease. Mem. Inst. Oswaldo. Cruz., 2009, 104 Suppl 1, 263-269.
10. Murcia, L.; Carrilero, B.; Segovia, M., Limitations of currently available Chagas disease chemotherapy. Rev. Esp. Quimioter., 2012, 25(1), 1-3.
11. Rodriques Coura, J.; de Castro, S. L., A critical review on Chagas disease chemotherapy. Mem. Inst. Oswaldo. Cruz., 2002, 97(1), 3-24.
12. Urbina, J. A.; Docampo, R., Specific chemotherapy of Chagas disease: controversies and advances. Trends Parasitol, 2003, 19(11), 495-501.
13. Bustamante, J. M.; Tarleton, R. L., Potential new clinical therapies for Chagas disease. Expert Rev. Clin. Pharmacol., 2014, 7(3), 317-325.
14. Ekins, S.; Williams, A. J.; Krasowski, M. D.; Freundlich, J. S., In silico repositioning of approved drugs for rare and neglected diseases. Drug Discov. Today, 2011, 16(7-8), 298-310.
15. Swamidass, S. J., Mining small-molecule screens to repurpose drugs. Brief Bioinform., 2011, 12(4), 327-335.
16. Allison, M., NCATS launches drug repurposing program. Nat. Biotechnol., 2012, 30(7), 571-572.
17. Marusina, K.; Welsch, D. J.; Rose, L.; Brock, D.; Bahr, N., The CTSA Pharmaceutical Assets Portal-a public-private partnership model for drug repositioning. Drug Discov. Today Ther. Strateg, 2011, 8(3-4), 77-83.
18. Novac, N., Challenges and opportunities of drug repositioning. Trends Pharmacol. Sci., 2013, 34(5), 267-272.
19. Ashburn, T. T.; Thor, K. B., Drug repositioning: identifying and developing new uses for existing drugs. Nat. Rev. Drug Discov., 2004, 3(8), 673-683.
20. Aube, J., Drug repurposing and the medicinal chemist. ACS Med. Chem. Lett., 2012, 3(6), 442-444.
21. Loging, W.; Rodriguez-Esteban, R.; Hill, J.; Freeman, T.; Miglietta, J., Chemoinformatic/Bioinformatic Analysis of Large Corporate Databases: Application to Drug Repurposing. Drug Discov. Today Ther. Strateg., 2011, 8, 109-116.
22. Carrieri, A.; Perez-Nueno, V. I.; Lentini, G.; Ritchie, D. W., Recent trends and future prospects in computational GPCR drug discovery: from virtual screening to polypharmacology. Curr. Top. Med. Chem., 2013, 13(9), 1069-1097.
23. Ma, D. L.; Chan, D. S.; Leung, C. H., Drug repositioning by structure-based virtual screening. Chem. Soc. Rev., 2013, 42(5), 2130-2141.
24. Temesi, G.; Bolgar, B.; Arany, A.; Szalai, C.; Antal, P.; Matyus, P., Early repositioning through compound set enrichment analysis: a knowledge-recycling strategy. Future Med. Chem., 2014, 6(5), 563-575.
25. Cho, Y.; Vermeire, J. J.; Merkel, J. S.; Leng, L.; Du, X.; Bucala, R.; Cappello, M.; Lolis, E., Drug repositioning and pharmacophore identification in the discovery of hookworm MIF inhibitors. Chem. Biol., 2011, 18(9), 1089-1101.
26. Debnath, A.; Ndao, M.; Reed, S. L., Reprofiled drug targets ancient protozoans: drug discovery for parasitic diarrheal diseases. Gut. Microbes, 2013, 4(1), 66-71.
27. Shahinas, D.; Liang, M.; Datti, A.; Pillai, D. R., A repurposing strategy identifies novel synergistic inhibitors of Plasmodium falciparum heat shock protein 90. J. Med. Chem., 2010, 53(9), 3552-3557.
28. Liu, Z.; Fang, H.; Reagan, K.; Xu, X.; Mendrick, D. L.; Slikker, W., Jr.; Tong, W., In silico drug repositioning: what we need to know. Drug Discov. Today, 2013, 18(3-4), 110-115.
29. Koonin, E. V., Orthologs, paralogs, and evolutionary genomics. Annu. Rev. Genet., 2005, 39, 309-338.
30. Qu, X. A.; Rajpal, D. K., Applications of Connectivity Map in drug discovery and development. Drug Discov. Today, 2012, 17(23-24), 1289-1298.
31. Lamb, J.; Crawford, E. D.; Peck, D.; Modell, J. W.; Blat, I. C.; Wrobel, M. J.; Lerner, J.; Brunet, J. P.; Subramanian, A.; Ross, K. N.; Reich, M.; Hieronymus, H.; Wei, G.; Armstrong, S. A.; Haggarty, S. J.; Clemons, P. A.; Wei, R.; Carr, S. A.; Lander, E. S.; Golub, T. R., The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science, 2006, 313(5795), 1929-1935.
32. Montero-Melendez, T.; Perretti, M., Connections in pharmacology: innovation serving translational medicine. Drug Discov. Today, 2014, 19(7), 820-823.
33. Chung, F. H.; Chiang, Y. R.; Tseng, A. L.; Sung, Y. C.; Lu, J.; Huang, M. C.; Ma, N.; Lee, H. C., Functional Module Connectivity Map(FMCM): a framework for searching repurposed drug compounds for systems treatment of cancer and an application to colorectal adenocarcinoma. PLoS One, 2014, 9(1), e86299.
34. Cha, K.; Kim, M. S.; Oh, K.; Shin, H.; Yi, G. S., Drug similarity search based on combined signatures in gene expression profiles. Healthc. Inform. Res., 2014, 20(1), 52-60.
35. Parkkinen, J. A.; Kaski, S., Probabilistic drug connectivity mapping. BMC Bioinformatics, 2014, 15, 113.
36. Haupt, V. J.; Daminelli, S.; Schroeder, M., Drug promiscuity in PDB: protein binding site similarity is key. Plos One, 2013, 8(6), e65894. http://www. plosone. org/article/info%3Adoi%2F10. 1371% 2Fjournal. pone. 0065894.
37. Talevi, A.; Castro, E. A.; Bruno-Blanch, L. E., Virtual Screening: An emergent, key methodology for drug development in an emergent continent-A bridge towards patentability. In Advanced Methods and Applications in Chemoinformatics, Castro, E. A.; Haghi, A. K., Eds. IGI Global 2011; pp 229-245.
38. Speck-Planche, A.; Kleandrova, V. V.; Cordeiro, M. N., New insights toward the discovery of antibacterial agents: multi-tasking QSBER model for the simultaneous prediction of anti-tuberculosis activity and toxicological profiles of drugs. Eur. J. Pharm. Sci., 2013, 48(4-5), 812-818.
39. Speck-Planche, A.; Kleandrova, V. V.; Luan, F.; Cordeiro, M. N., A ligand-based approach for the in silico discovery of multi-target inhibitors for proteins associated with HIV infection. Mol. Biosyst., 2012, 8(8), 2188-2196.
40. Speck-Planche, A.; Kleandrova, V. V.; Luan, F.; Cordeiro, M. N., Unified multi-target approach for the rational in silico design of antibladder cancer agents. Anticancer Agents Med. Chem., 2013, 13(5), 791-800.
41. Garcia, I.; Fall, Y.; Gomez, G.; Gonzalez-Diaz, H., First computational chemistry multi-target model for anti-Alzheimer, anti-parasitic, anti-fungi, and anti-bacterial activity of GSK-3 inhibitors in vitro, in vivo, and in different cellular lines. Mol. Divers., 2011, 15(2), 561-567.
42. Speck-Planche, A.; Kleandrova, V. V.; Luan, F.; Cordeiro, M. N., Rational drug design for anti-cancer chemotherapy: multi-target QSAR models for the in silico discovery of anti-colorectal cancer agents. Bioorg. Med. Chem., 2012, 20(15), 4848-4855.
43. Drwal, M. N.; Griffith, R., Combination of ligand-and structurebased methods in virtual screening. Drug Discov. Today Technol., 2013, 10(3), e395-401.
44. Good, A. C.; Hermsmeier, M. A.; Hindle, S. A., Measuring CAMD technique performance: a virtual screening case study in the design of validation experiments. J. Comput. Aided Mol. Des., 2004, 18(7-9), 529-536.
45. Hu, G.; Kuang, G.; Xiao, W.; Li, W.; Liu, G.; Tang, Y., Performance evaluation of 2D fingerprint and 3D shape similarity methods in virtual screening. J. Chem. Inf. Model, 2012, 52(5), 1103-1113.
46. Kalaszi, A.; Szisz, D.; Imre, G.; Polgar, T., Screen3D: a novel fully flexible high-throughput shape-similarity search method. J. Chem. Inf. Model, 2014, 54(4), 1036-1049.
47. Zhang, Q.; Muegge, I., Scaffold hopping through virtual screening using 2D and 3D similarity descriptors: ranking, voting, and consensus scoring. J. Med. Chem., 2006, 49(5), 1536-1548.
48. Knox, C.; Law, V.; Jewison, T.; Liu, P.; Ly, S.; Frolkis, A.; Pon, A.; Banco, K.; Mak, C.; Neveu, V.; Djoumbou, Y.; Eisner, R.; Guo, A. C.; Wishart, D. S., DrugBank 3. 0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res., 2011, 39(Database issue), D1035-1041.
49. Novick, P. A.; Ortiz, O.; Poelman, J.; Abdulhay, A. Y.; Pande, V. S., SWEETLEAD: an in silico database of approved drugs, regulated chemicals, and herbal isolates for computeraided drug discovery. PloS One, 2013, 8(11), e79568. http://www. plosone. org/article/info%3Adoi%2F10. 1371%2Fjournal. pone. 0079568.
50. Huang, R.; Southall, N.; Wang, Y.; Yasgar, A.; Shinn, P.; Jadhav, A.; Nguyen, D. T.; Austin, C. P., The NCGC pharmaceutical collection: a comprehensive resource of clinically approved drugs enabling repurposing and chemical genomics. Sci. Transl. Med., 2011, 3(80), 80ps16.
51. Wu, L.; Ai, N.; Liu, Y.; Wang, Y.; Fan, X., Relating anatomical therapeutic indications by the ensemble similarity of drug sets. J. Chem. Inf. Model, 2013, 53(8), 2154-2160.
52. Keiser, M. J.; Roth, B. L.; Armbruster, B. N.; Ernsberger, P.; Irwin, J. J.; Shoichet, B. K., Relating protein pharmacology by ligand chemistry. Nat. Biotechnol., 2007, 25(2), 197-206.
53. Keiser, M. J.; Setola, V.; Irwin, J. J.; Laggner, C.; Abbas, A. I.; Hufeisen, S. J.; Jensen, N. H.; Kuijer, M. B.; Matos, R. C.; Tran, T. B.; Whaley, R.; Glennon, R. A.; Hert, J.; Thomas, K. L.; Edwards, D. D.; Shoichet, B. K.; Roth, B. L., Predicting new molecular targets for known drugs. Nature, 2009, 462(7270), 175-181.
54. Wei, C.; Chen, K.; Chen, L., Mining biomedical literature and ontologies for drug repositioning discovery. In Advances in Knowledge Discovery and Data Mining, Tseng, V. S.; Ho, T. B.; Zhi-Hua; Zhou, Z.; Chen, A. L. P.; Hung-Yu; Kao, H., Eds. Springer: 2014; Vol. 8444, pp 373-384.
55. Deftereos, S. N.; Andronis, C.; Friedla, E. J.; Persidis, A., Drug repurposing and adverse event prediction using high-throughput literature analysis. Wiley Interdiscip. Rev. Syst. Biol. Med., 2011, 3(3), 323-334.
56. Lekka, E.; Deftereos, S. N.; Persidis, A.; Persidis, A.; Andronis, C., Literature analysis for systematic drug repurposing: A case study from Biovista. Drug Discovery Today: Therapeutic Strategies, 2012, 8(3-4), 103-108.
57. Vidal, M.; Cusick, M. E.; Barabasi, A. L., Interactome network and human disease. Cell, 2011, 144(6), 987-998.
58. Iskar, M.; Zeller, G.; Zhao, X.; van Noort, V.; Bork, P., Drug discovery in the age of systems biology: the rise of computational approaches for data integration. Curr. Opin. Biotech., 2012, 23(4), 609-616.
59. Chen, B.; Ding, Y.; Wild, D., Assessing Drug Target Association Using Semantic Linked Data. PLoS Comput Biol., 2012, 8(7), e1002574 http://www. ploscompbiol. org/article/info%3Adoi% 2F10. 1371%2Fjournal. pcbi. 1002574.
60. Lepesheva, G. I.; Villalta, F.; Waterman, M. R., Targeting Trypanosoma cruzi sterol 14alpha-demethylase(CYP51). Adv. Parasitol., 2011, 75, 65-87.
61. Roberts, C. W.; McLeod, R.; Rice, D. W.; Ginger, M.; Chance, M. L.; Goad, L. J., Fatty acid and sterol metabolism: potential antimicrobial targets in apicomplexan and trypanosomatid parasitic protozoa. Mol. Biochem. Parasitol., 2003, 126(2), 129-142.
62. Urbina, J. A., Ergosterol biosynthesis and drug development for Chagas disease. Mem. Inst. Oswaldo. Cruz., 2009, 104 Suppl 1, 311-318.
63. Lepesheva, G. I., Design or screening of drugs for the treatment of Chagas disease: what shows the most promise? Expert Opin. Drug Discov., 2013, 8(12), 1479-1489.
64. Buckner, F. S.; Urbina, J. A., Recent Developments in Sterol 14-demethylase Inhibitors for Chagas Disease. Int. J. Parasitol. Drugs Drug Resist., 2012, 2, 236-242.
65. Tarral, A.; Blesson, S.; Mordt, O. V.; Torreele, E.; Sassella, D.; Bray, M. A.; Hovsepian, L.; Evene, E.; Gualano, V.; Felices, M.; Strub-Wourgaft, N., Determination of an optimal dosing regimen for fexinidazole, a novel oral drug for the treatment of human African trypanosomiasis: first-in-human studies. Clin. Pharmacokinet., 2014, 53(6), 565-580.
66. Bahia, M. T.; de Andrade, I. M.; Martins, T. A.; do Nascimento, A. F.; Diniz Lde, F.; Caldas, I. S.; Talvani, A.; Trunz, B. B.; Torreele, E.; Ribeiro, I., Fexinidazole: a potential new drug candidate for Chagas disease. PLoS Negl. Trop. Dis., 2012, 6(11), e1870.
67. Haedo, A. H.; Chiale, P. A.; Bandieri, J. D.; Lazzari, J. O.; Elizari, M. V.; Rosenbaum, M. B., Comparative antiarrhythmic efficacy of verapamil, 17-monochloracetylajmaline, mexiletine and amiodarone in patients with severe chagasic myocarditis: relation with the underlying arrhythmogenic mechanisms. J. Am. Coll. Cardiol., 1986, 7(5), 1114-1120.
68. Benaim, G.; Sanders, J. M.; Garcia-Marchan, Y.; Colina, C.; Lira, R.; Caldera, A. R.; Payares, G.; Sanoja, C.; Burgos, J. M.; Leon-Rossell, A.; Concepcion, J. L.; Schijman, A. G.; Levin, M.; Oldfield, E.; Urbina, J. A., Amiodarone has intrinsic anti-Trypanosoma cruzi activity and acts synergistically with posaconazole. J. Med. Chem., 2006, 49(3), 892-899.
69. Benaim, B.; Garcia, C. R., Targeting calcium homeostasis as the therapy of Chagas' disease and leishmaniasis-a review. Trop. Biomed., 2011, 28(3), 471-481.
70. Benaim, G.; Paniz Mondolfi, A. E., The emerging role of amiodarone and dronedarone in Chagas disease. Nat. Rev. Cardiol., 2012, 9(10), 605-609.
71. Paniz-Mondolfi, A. E.; Perez-Alvarez, A. M.; Lanza, G.; Marquez, E.; Concepcion, J. L., Amiodarone and itraconazole: a rational therapeutic approach for the treatment of chronic Chagas' disease. Chemotherapy, 2009, 55(4), 228-233.
72. Adesse, D.; Azzam, E. M.; Meirelles Mde, N.; Urbina, J. A.; Garzoni, L. R., Amiodarone inhibits Trypanosoma cruzi infection and promotes cardiac cell recovery with gap junction and cytoskeleton reassembly in vitro. Antimicrob. Agents Chemother., 2011, 55(1), 203-210.
73. Bellera, C. L.; Balcazar, D. E.; Alberca, L.; Labriola, C. A.; Talevi, A.; Carrillo, C., Application of computer-aided drug repurposing in the search of new cruzipain inhibitors: discovery of amiodarone and bromocriptine inhibitory effects. J. Chem. Inf. Model, 2013, 53(9), 2402-2408.
74. Benaim, G.; Hernandez-Rodriguez, V.; Mujica-Gonzalez, S.; Plaza-Rojas, L.; Silva, M. L.; Parra-Gimenez, N.; Garcia-Marchan, Y.; Paniz-Mondolfi, A.; Uzcanga, G., In vitro anti-Trypanosoma cruzi activity of dronedarone, a novel amiodarone derivative with an improved safety profile. Antimicrob. Agents Chemother., 2012, 56(7), 3720-3725.
75. Garzoni, L. R.; Caldera, A.; Meirelles Mde, N.; de Castro, S. L.; Docampo, R.; Meints, G. A.; Oldfield, E.; Urbina, J. A., Selective in vitro effects of the farnesyl pyrophosphate synthase inhibitor risedronate on Trypanosoma cruzi. Int. J. Antimicrob. Agents, 2004, 23(3), 273-285.
76. Garzoni, L. R.; Waghabi, M. C.; Baptista, M. M.; de Castro, S. L.; Meirelles Mde, N.; Britto, C. C.; Docampo, R.; Oldfield, E.; Urbina, J. A., Antiparasitic activity of risedronate in a murine model of acute Chagas' disease. Int. J. Antimicrob. Agents, 2004, 23(3), 286-290.
77. Demoro, B.; Caruso, F.; Rossi, M.; Benitez, D.; Gonzalez, M.; Cerecetto, H.; Parajon-Costa, B.; Castiglioni, J.; Galizzi, M.; Docampo, R.; Otero, L.; Gambino, D., Risedronate metal complexes potentially active against Chagas disease. J. Inorg. Biochem., 2010, 104(12), 1252-1258.
78. Planer, J. D.; Hulverson, M. A.; Arif, J. A.; Ranade, R. M.; Don, R.; Buckner, F. S., Synergy testing of FDA-approved drugs identifies potent drug combinations against Trypanosoma cruzi. PLoS Negl. Trop. Dis., 2014, 8(7), e2977.
79. Bellera, C.; Balcazar, D.; Vanrell, M.; Casassa, F.; Labriola, C.; Galvez, J.; Bruno-Blanch, L.; Romano, P.; Carrillo, C.; Talevi, A., Knowledge-based drug repurposing: identification of antichagasic activity of clofazimine, benidipine and saquinavir. Submitted 2014.
80. Bellera, C. L.; Balcazar, D. E.; Alberca, L.; Labriola, C. A.; Talevi, A.; Carrillo, C., Identification of levothyroxine antichagasic activity through computer-aided drug repurposing. Scientific World Journal, 2014, 2014, 279618.
81. Yao, K.; Nagashima, K.; Miki, H., Pharmacological, pharmacokinetic, and clinical properties of benidipine hydrochloride, a novel, long-acting calcium channel blocker. J. Pharmacol. Sci., 2006, 100(4), 243-261.
82. Asanuma, H.; Kitakaze, M.; Node, K.; Takashima, S.; Sakata, Y.; Asakura, M.; Sanada, S.; Shinozaki, Y.; Mori, H.; Tada, M.; Kuzuya, T.; Hori, M., Benidipine, a long-acting Ca channel blocker, limits infarct size via bradykinin-and NO-dependent mechanisms in canine hearts. Cardiovasc. Drugs Ther., 2001, 15(3), 225-231.
83. Gao, F.; Gong, B.; Christopher, T. A.; Lopez, B. L.; Karasawa, A.; Ma, X. L., Anti-apoptotic effect of benidipine, a long-lasting vasodilating calcium antagonist, in ischaemic/reperfused myocardial cells. Br. J. Pharmacol., 2001, 132(4), 869-878.
84. Liu, H. R.; Gao, F.; Tao, L.; Yan, W. L.; Gao, E.; Christopher, T. A.; Lopez, B. L.; Hu, A.; Ma, X. L., Antiapoptotic mechanisms of benidipine in the ischemic/reperfused heart. Br. J. Pharmacol., 2004, 142(4), 627-634.
85. Wang, N.; Minatoguchi, S.; Chen, X. H.; Arai, M.; Uno, Y.; Lu, C.; Misao, Y.; Nagai, H.; Takemura, G.; Fujiwara, H., Benidipine reduces myocardial infarct size involving reduction of hydroxyl radicals and production of protein kinase C-dependent nitric oxide in rabbits. J. Cardiovasc. Pharmacol., 2004, 43(6), 747-757.
86. Reimao, J. Q.; Scotti, M. T.; Tempone, A. G., Anti-leishmanial and anti-trypanosomal activities of 1, 4-dihydropyridines: In vitro evaluation and structure-activity relationship study. Bioorg. Med. Chem., 2010, 18(22), 8044-8053.
87. Cholo, M. C.; Steel, H. C.; Fourie, P. B.; Germishuizen, W. A.; Anderson, R., Clofazimine: current status and future prospects. J. Antimicrob. Chemother., 2012, 67(2), 290-298.